Effect of chronic arsenic exposure from drinking waters on the QT interval and transmural dispersion of repolarization

Journal of International Medical Research

Volumn 36, Issue 3, 2008, Pages 471-478

  Yildiz, Ahmet ^a   Karaca, M ^b   Biceroglu, S ^b   Nalbantcilar, M T ^c   Coskun, U ^d   Arik, F ^c   Aliyev, F ^d   Yiginer, O ^e   Turkoglu, C ^d  

^a Gazi Hospital   (Turkey)

^b Atakalp Kalp Hastaliklari Hastanesi Kahramanlar   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Istanbul Science University   (Turkey)

Author keywords

Arrhythmia; ArsenicArsenic; Drinking water; QT interval; Repolarization; Transmural dispersion

Indexed keywords

ARSENIC; DRINKING WATER; LIPID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QT INTERVAL; QT PROLONGATION; TURKEY (REPUBLIC); WATER ANALYSIS; WATER CONTAMINATION; WATER SAMPLING;

EID: 45149095340     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600311     Document Type: Article

References (32)

1. Ishinishi N, Tsuchiya K, Vahter M, et al: Arsenic. In: Handbook of the Toxicology of Metals, Vol II (Frieberg L, Nordberg GF, Vouk BV, eds). Amsterdam: Elsevier, 1986; pp 43-73.
2. DeMarini DM, Kligerman AD, Doerr CL, et al: Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen 2003; 42: 192-205.
3. World Health Organization: Environmental Health Criteria 18, Arsenic. Geneva: World Health Organization, 1981; pp 43-102.
4. US Environmental Protection Agency: National Primary Drinking Water Standards. Washington: US Environmental Protection Agency, Office of Water (4606M) EPA 816-F-03-016, June 2003.
5. Tseng WP: Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977; 19: 109-119.
6. Ross R: The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488-500.
7. Chen CJ, Chiou HY, Chiang MH, et al: Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 1996; 16: 504-510.
8. Chiou HY, Huang WI, Su CL, et al: Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 1997; 28: 1717-1723.
9. Ahmad SA, Khatun F, Sayed MH, et al: Electrocardiographic abnormalities among arsenic-exposed persons through groundwater in Bangladesh. J Health Popul Nutr 2006; 24: 221-227.
10. Chang CC, Ho SC, Tsai SS, et al: Ischemic heart disease mortality reduction in an arseniasis-endemic area in southwestern Taiwan after a switch in the tap-water supply system. Toxicol Environ Health 2004; 67: 1353-1361.
11. Navas-Acien A, Shorrett AR, Silbergeld EK, et al: Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 2006; 164: 194-195; author reply 195-196.
12. Yu HS, Liao WT, Chai CY: Arsenic carcinogenesis in the skin. J Biomed Sci 2006; 13: 657-666.
13. Smith AH, G Marshall, Yuan Y, et al: Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect 2006; 114: 1293-1296.
14. Tseng WP: Effects and dose-response relationship of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977; 19: 109-119.
15. Ohnishi K, Yoshida H, Shingeno K, et al: Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881-885.
16. Unnikrishnan D, Dutcher JP, Varshneya N, et al: Torsades de pointes in 3 patients with leukemia treated with arsenic poisoning. Blood 2001; 97: 1514-1516.
17. Little RE, Kay GN, Cavender JB, et al: Torsade de pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin Electrophysiol 1990; 13: 164-170.
18. Rodriguez I, Kilborn MJ, Liu X, et al: Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
19. ACME Analytical Laboratories: Methods and Specifications for Analytical Package. Group 2C & 2D - Water Analysis by ICP-MS, 2005.
20. American Public Health Association: Standard Methods for the Examination of Water and Wastewater. Washington DC: American Public Health Association, 1992.
21. Bazzet HC: An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
22. World Health Organization: Health criteria and other supporting information. Guidelines for Drinking-water Quality, 2nd edn. Geneva: World Health Organization, 1996; pp 940-949.
23. Ficker E, Kuryshev YA, Dennis AT, et al: Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33-44.
24. Mumford JL, Wu K, Xia Y, et al: Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect 2007; 115: 690-694.
25. Engström SK, Broberg K, Gabriela C, et al: Genetic polymorphism influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 2007; 115: 599-605.
26. Antzelevitch C: T peak-T end interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 2001; 31: 555-557.
27. Wolk R, Stec S, Kulakowski P: Extrasystolic beats affect transmural electrical dispersion during programmed electrical stimulation. Eur J Clin Invest 2001; 31: 293-301.
28. Tanabe Y, Inagaki M, Kurita T, et al: Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2001; 37: 911-919.
29. Frederiks J, Swenne CA, Kors JA, et al: Within-subject electrocardiographic differences at equal heart rates: role of the autonomic nervous system. Pflugers Arch 2001; 441: 717-724.
30. Shimizu M, Ino H, Okeie K, et al: T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol 2002; 25: 335-339.
31. Takenaka K, Ai T, Shimizu W, et al: Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107: 838-844.
32. Watanabe N, Kobayashi Y, Tanno K, et al: Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol 2004; 37: 191-200.